Michael L Spector

US Patent:

7680725, Mar 16, 2010

Filed:

Jul 20, 2007

Appl. No.:

11/780588

Inventors:

Steven M. Bloom - Springfield NJ, US
Michael S. Spector - Washington DC, US
John L. Jacobs - Columbia MD, US

Assignee:

The NASDAQ OMX Group, Inc. - Rockville MD

International Classification:

G06Q 40/00

US Classification:

705 37

Abstract:

A financial product is based on a first fund that is traded on a trading marketplace in a first country. The financial product is registered in the first country. The first fund has the characteristics of being based on an index of securities that are traded in a second, different country. The first fund is arbitragable with a second fund that is based on the index and which is registered in a second different country. The first fund has a creation unit basis that is substantially the same basis as a creation unit basis for the second fund. The calculation of the net asset value of the first fund occurs at essentially or exactly the same time that second country fund has its NAV calculated.

US Patent:

7809627, Oct 5, 2010

Filed:

Feb 15, 2002

Appl. No.:

10/077182

Inventors:

Steven M. Bloom - Springfield NJ, US
Michael S. Spector - Washington DC, US
John L Jacobs - Columbia MD, US

Assignee:

The Nasdaq OMX Group, Inc. - Rockville MD

International Classification:

G06Q 40/00

US Classification:

705 37

Abstract:

A financial product is based on a first fund that is traded on a trading marketplace in a first country. The financial product is registered in the first country. The first fund has the characteristics of being based on an index of securities that are traded in a second, different country. The first fund is arbitragable with a second fund that is based on the index and which is registered in a second different country. The first fund has a creation unit basis that is substantially the same basis as a creation unit basis for the second fund. The calculation of the net asset value of the first fund occurs at essentially or exactly the same time that second country fund has its NAV calculated. The agent for the first fund has the option of providing or accepting second fund shares or other securities, rather than cash, to cover “cash amount” obligations. Such obligations arise from the need to equate the value received or given for the first fund shares (e. g.

US Patent:

7813992, Oct 12, 2010

Filed:

Nov 14, 2001

Appl. No.:

10/001900

Inventors:

Steven M. Bloom - Springfield NJ, US
Michael S. Spector - Washington DC, US
John L. Jacobs - Columbia MD, US

Assignee:

The Nasdaq OMX Group, Inc. - Rockville MD

International Classification:

G06Q 40/00

US Classification:

705 37

Abstract:

A financial product is based on a first fund that is traded on a trading marketplace in a first country. The financial product is registered in the first country. The first fund has the characteristics of being based on an index of securities that are traded in a second, different country. The first fund is arbitragable with a second fund that is based on the index and which is registered in a second different country. The first fund has a creation unit basis that is substantially the same basis as a creation unit basis for the second fund. The calculation of the net asset value of the first fund occurs at essentially or exactly the same time that second country fund has its NAV calculated.

US Patent:

7983983, Jul 19, 2011

Filed:

Mar 16, 2010

Appl. No.:

12/724607

Inventors:

Steven M. Bloom - Springfield NJ, US
Michael S. Spector - Washington DC, US
John L. Jacobs - Columbia MD, US

Assignee:

The NASDAQ OMX Group, Inc. - Rockville MD

International Classification:

G06Q 40/00

US Classification:

705 37

Abstract:

A financial product is based on a first fund that is traded on a trading marketplace in a first country. The financial product is registered in the first country. The first fund has the characteristics of being based on an index of securities that are traded in a second, different country. The first fund is arbitragable with a second fund that is based on the index and which is registered in a second different country. The first fund has a creation unit basis that is substantially the same basis as a creation unit basis for the second fund. The calculation of the net asset value of the first fund occurs at essentially or exactly the same time that second country fund has its NAV calculated.

US Patent:

7983985, Jul 19, 2011

Filed:

Oct 5, 2010

Appl. No.:

12/897856

Inventors:

Steven M. Bloom - Springfield NJ, US
Michael S. Spector - Washington DC, US
John L. Jacobs - Columbia MD, US

Assignee:

The NASDAQ OMX Group, Inc. - Rockville MD

International Classification:

G06Q 40/00

US Classification:

705 37, 705 36 R

Abstract:

A financial product is based on a first fund that is traded on a trading marketplace in a first country. The financial product is registered in the first country. The first fund has the characteristics of being based on an index of securities that are traded in a second, different country. The first fund is arbitragable with a second fund that is based on the index and which is registered in a second different country. The first fund has a creation unit basis that is substantially the same basis as a creation unit basis for the second fund. The calculation of the net asset value of the first fund occurs at essentially or exactly the same time that second country fund has its NAV calculated. The agent for the first fund has the option of providing or accepting second fund shares or other securities, rather than cash, to cover “cash amount” obligations. Such obligations arise from the need to equate the value received or given for the first fund shares (e. g.

US Patent:

20020091616, Jul 11, 2002

Filed:

Jan 11, 2001

Appl. No.:

09/758967

Inventors:

Steven Bloom - Springfield NJ, US
Michael Spector - Washington DC, US
John Jacobs - Columbia MD, US

International Classification:

G06F017/60

US Classification:

705/037000

Abstract:

A financial product is based on a first fund that is traded on a trading marketplace in a first country. The financial product is registered in the first country. The first fund has the characteristics of being based on an index of securities that are traded in a second, different country. The first fund is arbitragable with a second fund that is based on the index and which is registered in a second different country. The first fund has a creation unit basis that is substantially the same basis as a creation unit basis for the second fund. The calculation of the net asset value of the first fund occurs at essentially or exactly the same time that second country fund has its NAV calculated.

US Patent:

20200330441, Oct 22, 2020

Filed:

Jul 7, 2020

Appl. No.:

16/922712

Inventors:

Michael Spector - Shamong NJ, US
- Pittsburgh PA, US

International Classification:

A61K 31/43
A61K 31/424
A61P 31/04
A61P 31/00
A61P 27/16
A61K 45/06

Abstract:

The invention is directed to a pediatric oral suspension composition containing amoxicillin and clavulanate potassium where the clavulanate potassium is present in an amount equal to or less than about 21.5 mg/5 mL, and a method of treating bacterial infections by providing between about one to about fourteen dosage days of the composition. Also disclosed are methods of treating a patient comprising administering amoxicillin and clavulanate potassium to the patient in dosages of at least about 80 mg/kg/day of the amoxicillin and from about 1.66 mg/kg/day to about 2.84 mg/kg/day of the clavulanate potassium. The methods are useful for treating pediatric otitis media, treating a drug resistant bacterial infection, or treating beta-lactamase producing or in a patient under 24 months of age.

US Patent:

20160339002, Nov 24, 2016

Filed:

Jan 10, 2013

Appl. No.:

14/371731

Inventors:

Michael Spector - Shamong NJ, US
Alejandro Hoberman - Wexford PA, US

International Classification:

A61K 31/43
A61K 9/00
A61K 31/424
A61K 9/10

Abstract:

The invention is directed to a pediatric oral suspension composition containing amoxicillin and clavulanate potassium where the clavulanate potassium is present in an amount equal to or less than about 21.5 mg/5 mL, and a method of treating bacterial infections by providing between about one to about fourteen dosage days of the composition.